Physical or chemical interactions between enteral feeding solutions and drugs are uncommon but may lead to relatively serious complications. We report a case of total oesophageal obstruction in a patient receiving Sucralfate suspension and Ensure Plus enteral feed.
CASE REPORT
A 65-year-old man with pneumonia and ARDS who was receiving parenteral nutrition developed haemorrhagic gastritis which was treated with Sucralfate suspension (A.H. Robins, UK) 1 g six-hourly via a nasogastric tube. Later enteral feeding was introduced with Ensure Plus (Abbott, UK) and Sucralfate was continued for a further 14 days until the nasogastric tube blocked completely. It was impossible to insert a new nasogastric tube. Fibreoptic endoscopy revealed the distal oesophagus to be completely blocked by large amounts of creamy-white matter (Figure 1 ). The material was too thick to be aspirated by the fibreoptic endoscope and was removed piecemeal via a rigid oesophagoscope using biopsy forceps. The material had the odour of Ensure Plus. Further fibreoptic endoscopy showed the stomach to be caked with the same material and the stomach contents were lavaged with water. The Sucralfate was stopped but nasogastric enteral feeding with Ensure Plus continued. Repeat endoscopy 14 days later showed the oesophagus and stomach to have remained clear. Enteral feeding continued uneventfully thereafter. At the time of oesophageal obstruction the patient was also receiving midazolam for sedation and had received omnopon and ciprofioxacin previously.
We then investigated the miscibility of Sucralfate suspension and Ensure Plus, and the effect of acidity on both and on the mixture of the two, 
METHOD
Sucralfate suspension and Ensure Plus were mixed in the proportions 1:5, 1:10, 1:15, 1:20 and 1:25 and left to stand for two hours at 37°C and observed for changes in appearance and consistency. The 1 :20 mixture represents 1 g Sucralfate suspension 5 ml and Ensure Plus 100 ml. Secondly, increasing amounts of 1 molar hydrochloric acid were added to 5 ml of the 1:20 mixture of Sucralfate and Ensure Plus, Sucralfate alone and Ensure Plus alone. The change in consistency of the mixture was noted and the pH when a change occurred measured using a Corning 220 pH meter.
RESULTS
There was no change in appearance or consistency when Sucralfate and Ensure Plus were mixed in the proportions 1:5, 1:10, 1:15, 1:20 and 1:25 and left to stand for two hours at 37°C.
The results of adding 1 molar hydrochloric acid to 1:20 Sucralfate/Ensure Plus, Sucralfate alone and Ensure Plus alone are shown in Table 1 . As acidity increased, the 1:20 mixture of Sucralfate/Ensure Plus formed precipitates which then thickened and became semi-solid. Ensure Plus became increasingly thick and then gel-like. Sucralfate changed from a liquid to a thick gel with the addition of acid. The consistency of all was markedly thickened below pH 4.
It was notable that the observed changes in consistency occurred almost immediately acid was added. The factors which favour the formation of gastrointestinal bezoars are polypharmacy, dehydration, renal failure and delayed gastric emptying. Many of these factors are present in critically ill patients and have been present when bezoar formation has been attributed to the use of Sucralfate. 14 Additional considerations include physical or chemical interactions between drugs and enteral feeding solutions and the effect of gastric acidity on the latter. Anaesthesia and IlllenS;\'c Care, 1/0/. 21, .'\10. 3, June, 1993 Sucralfate is a complex of aluminium hydroxide and sulphated sucrose with weak antacid activity having no effect on intragastric pH. In the acidic milieu of the stomach aluminium ions dissociate and sucrose octasulphate polymerises and binds preferentially to ulcerated gastric mucosa.
There are several mechanisms by which Sucralfate ~ay have contributed to bezoar formation. First, the aluminium content of Sucralfate has been estimated at 18070 4 and intestinal obstruction due to aluminium bezoars has been reported before. 57 Second, aluminium hydroxide forms insoluble salts with dietary phosphate, precipitates protein and delays gastric emptying. 8 Third, oesophageal obstruction due to an interaction between protein-containing enteral feed and aluminium-containing antacids has been reported before-in certain proportions mixtures of the two are thixotropic, i.e. viscosity increases and gelling occurs. 9 This did not appear to be a factor in our case until the acidity of the mixture was increased.
We could not analyse the material removed from the oesophagus but assume that it consisted of Sucralfate and Ensure Plus and was not simply Sucralfate alone or Ensure Plus alone. This assumption is based on the temporal association between administering Sucralfate and Ensure Plus. The material closely resembled the mixture of the two and smelled of Ensure Plus, and after stopping Sucralfate but continuing Ensure Plus bezoar formation did not recur.
Our laboratory findings indicate that increasing acidity causes precipitation and increasing viscosity of the Sucralfate/Ensure Plus mixture, Sucralfate and Ensure Plus, particularly below a pH of 4. Other reports of oesophageal obstruction in association with enteral feed have shown that below a pH of 4 to 5, casein in enteral feeds is precipitated. 10, 11 The lack of an antacid effect of Sucralfate would enable precipitation of Ensure Plus to occur in the presence of gastric acid. Since there were no further problems after stopping Sucralfate while continuing Ensure Plus, precipitation of Ensure Plus by gastric acid was not the cause of oesophageal obstruction. Sucralfate remains implicated, possibly by a combination of the second and third mechanisms outlined above.
The manufacturers of Sucralfate recommend that enteral feeding be discontinued for 30 minutes before and after administration of Sucralfate via the same nasogastric tube. We were unaware of this at the time. However, this would involve interrupting enteral feeding for up to four hours a day. If prophylaxis against stressinduced gastric ulceration is still considered necessary while enteral feeding is in progress, an H2 antagonist may be more practical.
